News

Public · Published

STRATEC SE (SBS) Sells Diatron For €10M, Books €44.1M Impairment, Lifts 2026 Margin Outlook

STRATEC SE agreed to sell Diatron MI for €10M, with potential earn-outs, or additional payments tied to future results. It will record €44.1M in non-cash impairments and a €4–9M negative deconsolidation effect, while guiding to a 2026 adjusted EBIT margin of 13–15% on stable to slightly higher sales.

Published:

Updated:

What happened

STRATEC SE agreed to sell Diatron MI for €10M, with potential earn-outs, or additional payments tied to future results. It will record €44.1M in non-cash impairments and a €4–9M negative deconsolidation effect, while guiding to a 2026 adjusted EBIT margin of 13–15% on stable to slightly higher sales.

Confirmed

Global impact / market context

The sale removes a unit described as loss-making, which could improve the profitability of the remaining business. However, the impairments and deconsolidation effect will weigh on reported earnings even though they are described as non-cash, while the higher margin outlook depends on execution.

Analyst inference

The outlook points to stronger profit per sale rather than rapid growth: 2026 sales are expected to be stable to slightly higher, alongside a 13–15% adjusted EBIT margin. Investors will need to distinguish these adjusted targets from reported results, which face one-time charges.

Analyst inference

What to watch

  1. Watch whether the Diatron MI sale closes on schedule and whether any earn-outs become payable; completion determines when the unit leaves STRATEC’s accounts. Analyst inference
  2. Track the €44.1M impairment and €4–9M deconsolidation effect in reported results; these are expected accounting charges, not cash payments, according to the article. Confirmed
  3. Compare 2026 sales and adjusted EBIT margin with the guidance of stable to slightly higher sales and 13–15%; delivery would test the margin-focused plan. Analyst inference

Evidence